Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
The Methodist Hospital Research Institute
IO Biotech
Merck Sharp & Dohme LLC
Dragonfly Therapeutics
Seagen Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
University of Leipzig
University of California, San Diego
Merck Sharp & Dohme LLC
University of California, San Diego
Cue Biopharma
Washington University School of Medicine
Seoul National University Hospital
University of Pittsburgh
Immutep S.A.S.
Merck Sharp & Dohme LLC
Incyte Corporation
Wake Forest University Health Sciences
Merck Sharp & Dohme LLC
Dragonfly Therapeutics
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
University of Southern California
Sanford Health
PDS Biotechnology Corp.
BioAtla, Inc.
Hookipa Biotech GmbH
Tempest Therapeutics
Hookipa Biotech GmbH
Takeda
Calliditas Therapeutics AB
Academic and Community Cancer Research United
Merck Sharp & Dohme LLC
MacroGenics
Xencor, Inc.
Incyte Corporation
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Commonwealth Healthcare Corporation
Mural Oncology, Inc
M.D. Anderson Cancer Center
Thomas Jefferson University
Akamis Bio
GlaxoSmithKline
University of Pittsburgh
Intensity Therapeutics, Inc.
UNICANCER
Medical University of South Carolina